13440 Federal Register / Vol. 60, No. 48 / Monday, March 13, 1995 / Notices

Dated: March 8, 1995.

Linda A. Suydam,

Interim Deputy Commissioner for Operations.

[FR Doc. 95–6126 Filed 3–8–95; 4:20 pm]

BILLING CODE 4160–01–F

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: This notice announces a

forthcoming meeting of a public

advisory committee of the Food and

Drug Administration (FDA). This notice

also summarizes the procedures for the

meeting and methods by which

interested persons may participate in

open public hearings before FDA’s

advisory committees.

FDA has established an Advisory

Committee Information Hotline (the

hotline) using a voice-mail telephone

system. The hotline provides the public

with access to the most current

information on FDA advisory committee

meetings. The advisory committee

hotline, which will disseminate current

information and information updates,

can be accessed by dialing 1–800–741–

8138 or 301–443–0572. Each advisory

committee is assigned a 5-digit number.

This 5-digit number will appear in each

individual notice of meeting. The

hotline will enable the public to obtain

information about a particular advisory

committee by using the committee’s 5-

digit number. Information in the hotline

is preliminary and may change before a

meeting is actually held. The hotline

will be updated when such changes are

made.

MEETING: The following advisory

committee meeting is announced:

Vaccines and Related Biological

Products Advisory Committee

Date, time, and place. March 17,

1995, 3 p.m., Food and Drug

Administration, Bldg. 29, conference

room 121, 8800 Rockville Pike,

Bethesda, MD.

Type of meeting and contact person.

This meeting will be held by a

telephone conference call. A speaker

telephone will be provided in the

conference room to allow public

participation in the meeting. Open

committee discussion, 3 p.m. to 4:30

p.m.; open public hearing, 4:30 p.m. to

5:30 p.m., unless public participation

does not last that long; Nancy T. Cherry

or Stephanie A. Milwit, Center for

Biologics Evaluation and Research

(HFM–21), Food and Drug

Administration, 1401 Rockville Pike,

Rockville, MD 20852, 301–827–0314, or

FDA Advisory Committee Information

Hotline, 1–800–741–8138 (301–443–

0572 in the Washington, DC area),

Vaccines and Related Biological

Products Advisory Committee, code

12388.

General function of the committee.

The committee reviews and evaluates

data on the safety and effectiveness of

vaccines intended for use in the

diagnosis, prevention, or treatment of

human diseases.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

committee. Those desiring to make

formal presentations should notify the

contact person.

Open committee discussion. The

committee will discuss the influenza

virus vaccine formulation for 1995–

1996.

FDA regrets that it was unable to

publish this notice 15 days prior to the

March 17, 1995, Vaccines and Related

Biological Products Advisory

Committee meeting because of the need

to update the committee on late

developing influenza activity and to

formulate a vaccine for the 1995–1996

year based on that data while providing

manufacturers sufficient lead time to

develop and produce the vaccine. This

meeting is a followup to the January

1995 advisory committee meeting. The

agency decided that it was in the public

interest to hold this meeting in midMarch even if there was not sufficient

time for the customary 15-day public

notice.

FDA public advisory committee

meetings may have as many as four

separable portions: (1) An open public

hearing, (2) an open committee

discussion, (3) a closed presentation of

data, and (4) a closed committee

deliberation. Every advisory committee

meeting shall have an open public

hearing portion. Whether or not it also

includes any of the other three portions

will depend upon the specific meeting

involved. There are no closed portions

for the meetings announced in this

notice. The dates and times reserved for

the open portions of each committee

meeting are listed above.

The open public hearing portion of

each meeting shall be at least 1 hour

long unless public participation does

not last that long. It is emphasized,

however, that the 1 hour time limit for

an open public hearing represents a

minimum rather than a maximum time

for public participation, and an open

public hearing may last for whatever

longer period the committee

chairperson determines will facilitate

the committee’s work.

Public hearings are subject to FDA’s

guideline (subpart C of 21 CFR part 10)

concerning the policy and procedures

for electronic media coverage of FDA’s

public administrative proceedings,

including hearings before public

advisory committees under 21 CFR part

14. Under 21 CFR 10.205,

representatives of the electronic media

may be permitted, subject to certain

limitations, to videotape, film, or

otherwise record FDA’s public

administrative proceedings, including

presentations by participants.

Meetings of advisory committees shall

be conducted, insofar as is practical, in

accordance with the agenda published

in this Federal Register notice. Changes

in the agenda will be announced at the

beginning of the open portion of a

meeting.

Any interested person who wishes to

be assured of the right to make an oral

presentation at the open public hearing

portion of a meeting shall inform the

contact person listed above, either orally

or in writing, prior to the meeting. Any

person attending the hearing who does

not in advance of the meeting request an

opportunity to speak will be allowed to

make an oral presentation at the

hearing’s conclusion, if time permits, at

the chairperson’s discretion.

The agenda, the questions to be

addressed by the committee, and a

current list of committee members will

be available at the meeting location on

the day of the meeting.

Transcripts of the open portion of the

meeting may be requested in writing

from the Freedom of Information Office

(HFI–35), Food and Drug

Administration, rm. 12A–16, 5600

Fishers Lane, Rockville, MD 20857,

approximately 15 working days after the

meeting, at a cost of 10 cents per page.

The transcript may be viewed at the

Dockets Management Branch (HFA–

305), Food and Drug Administration,

rm. 1–23, 12420 Parklawn Dr.,

Rockville, MD 20857, approximately 15

working days after the meeting, between

the hours of 9 a.m. and 4 p.m., Monday

through Friday. Summary minutes of

the open portion of the meeting may be

requested in writing from the Freedom

of Information Office (address above)

beginning approximately 90 days after

the meeting.

This notice is issued under section

10(a)(1) and (2) of the Federal Advisory

Committee Act (5 U.S.C. app. 2), and

FDA’s regulations (21 CFR part 14) on

advisory committees.
Federal Register / Vol. 60, No. 48 / Monday, March 13, 1995 / Notices 13441

Dated: March 7, 1995

Linda A. Suydam,

Interim Deputy Commissioner for Operations.

[FR Doc. 95–6061 Filed 3–10–95; 8:45 am]

BILLING CODE 4160–01–F

Health Care Financing Administration

[BPD–833–N]

Medicare Program; Hospice Wage

Index

AGENCY: Health Care Financing

Administration (HCFA), HHS.

ACTION: Notice of meetings.

SUMMARY: In accordance with section

10(a) of the Federal Advisory Committee

Act (FACA), this notice announces two

meetings of the Negotiated Rulemaking

Advisory Committee on the Medicare

Hospice Wage Index. The meetings are

open to the public.

DATES: The March meeting is scheduled

for March 22, 1995, from 10 a.m. until

5 p.m. e.s.t., and March 23, 1995, from

9 a.m. until 3 p.m. The April meeting

is scheduled for April 11, 1995, from 10

a.m. until 5 p.m. e.s.t., April 12, 1995,

from 9 a.m. until 5 p.m., and April 13,

1995, from 9 a.m. until 3 p.m.

ADDRESSES: The meetings will be held at

the Sheraton City Center, 1143 New

Hampshire Avenue NW., Washington,

DC 20037.

FOR FURTHER INFORMATION CONTACT:

Jennifer Carter, (410) 966–4615.

SUPPLEMENTARY INFORMATION: Under the

authority of the Negotiated Rulemaking

Act of 1990 (Pub. L. 101–648, 5 U.S.C.

581–590), the Secretary of the

Department of Health and Human

Services has established the Negotiated

Rulemaking Advisory Committee on the

Medicare Hospice Wage Index. The

Committee will make recommendations

with respect to the content of a

proposed rule on the wage index used

to adjust payment rates for hospice care

under the Medicare program to reflect

local differences in area wage levels.

The Committee consists of

representatives of interests that are

likely to be significantly affected by the

proposed rule.

The Committee will meet on March

22–23 and April 11–13, 1995. The

Committee will undertake the following

activities:

• Discussion of analyses using Bureau

of Labor Statistics data.

• Review issues in light of the BLS

and hospital data.

• Attempt to develop a consensus

document.

Individuals or organizations who

wish to attend the meeting or make oral

presentations may do so. However, the

number of presentations may be limited

by the time available. Individuals may

also submit written statements for the

Committee’s consideration. For

information on how to do this, please

contact the Committee facilitator, Judy

Ballard at (202) 690–7419.

(Section 10(a) of Public Law 92–463 (5 U.S.C.

App. 2, section 10(a)); 45 CFR Part 11

(Catalog of Federal Domestic Assistance

Program No. 93.773 Medicare—Hospital

Insurance Program)

Dated: March 7, 1995.

Bruce C. Vladeck,

Administrator, Health Care Financing

Administration.

[FR Doc. 95–6083 Filed 3–8–95; 12:34 pm]

BILLING CODE 4120–01–P

National Institutes of Health

Division of Research Grants; Notice of

Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Division

of Research Grants Special Emphasis

Panel (SEP) meetings:

Purpose/Agenda

To review individual grant applications.

Name of SEP: Clinical Sciences.

Date: March 29, 1995.

Time: 1 p.m.

Place: NIH, Westwood Building, Room

352, Telephone Conference.

Contact Person: Dr. Gertrude McFarland,

Scientific Review Admin., 5333 Westbard

Ave., Room 352, Bethesda, MD 20892; (301)

594–7080.

Name of SEP: Microbiological and

Immunological Sciences.

Date: April 11, 1995.

Time: 2 p.m.

Place: NIH, Westwood Building, Room

226, Telephone Conference.

Contact Person: Dr. Gerald Liddel,

Scientific Review Administrator, 5333

Westbard Ave., Room 226, Bethesda, MD

20892; (301) 594–7167.

Name of SEP: Microbiological and

Immunological Sciences.

Date: April 12, 1995.

Time: 1 p.m.

Place: NIH, Westwood Building, Room

226, Telephone Conference.

Contact Person: Dr. Gerald Liddel,

Scientific Review Administrator, 5333

Westbard Ave., Room 226, Bethesda, MD

20892; (301) 594–7167.

The meetings will be closed in

accordance with the provisions set forth

in secs. 552b(c)(4) and 552b(c)(6), Title

5, U.S.C. Applications and/or proposals

and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material

and personal information concerning

individuals associated with the

applications and/or proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

This notice is being published less

than 15 days prior to the meeting due

to the urgent need to meet timing

limitations imposed by the grant review

cycle.

(Catalog of Federal Domestic Assistance

Program Nos. 93.306, 93.333, 93.337, 93.393–

93.396, 93.837–93.844, 93.846–93.878,

93.892, 93.893, National Institutes of Health,

HHS)

Dated: March 3, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–6056 Filed 3–10–95; 8:45 am]

BILLING CODE 4140–01–M

Social Security Administration

Privacy Act of 1974, as Amended;

Computer Matching Program (SSA/

Railroad Retirement Board)

AGENCY: Social Security Administration,

HHS.

ACTION: Notice of computer matching

program.

SUMMARY: In accordance with the

provisions of the Privacy Act, as

amended, this notice announces a

computer matching program that SSA

plans to conduct.

DATES: SSA will file a report of the

subject matching program with the

Committee on Governmental Affairs of

the Senate, the Committee on

Government Reform and Oversight of

the House of Representatives and the

Office of Information and Regulatory

Affairs, Office of Management and

Budget. The matching program will be

effective as indicated below.

ADDRESSES: Interested parties may

comment on this notice by either

facsimile to (410) 966–5138, or writing

to the Associate Commissioner for

Program and Integrity Reviews, 860

Altmeyer Building, 6401 Security

Boulevard, Baltimore, MD 21235. All

comments received will be available for

public inspection at this address.

FOR FURTHER INFORMATION CONTACT: The

Associate Commissioner for Program

and Integrity Reviews as shown above.

SUPPLEMENTARY INFORMATION:

A. General

The Computer Matching and Privacy

Protection Act of 1988 (Pub. L. 100–

503), amended the Privacy Act (5 U.S.C.

552a) by adding certain protections for